5-MeO-PiPT

Last updated

5-MeO-PiPT
5-MeO-PiPT.svg
5-MeO-PiPT 3D.png
Clinical data
Other names5-Methoxy-N-propyl-N-isopropyltryptamine
Drug class Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-(propan-2-yl)propan-1-amine
CAS Number
PubChem CID
Chemical and physical data
Formula C17H26N2O
Molar mass 274.408 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC)CCc1c[NH]c2ccc(cc21)OC
  • InChI=1S/C17H26N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h6-7,11-13,18H,5,8-10H2,1-4H3
  • Key:KLRSMSBDLVDLKK-UHFFFAOYSA-N

5-MeO-PiPT, also known as 5-methoxy-N-propyl-N-isopropyltryptamine, is a substituted tryptamine derivative which is claimed to have psychedelic effects. [1] [2] It has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada. [3]

Contents

Use and effects

5-MeO-PiPT was not included or mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved). [4]

Interactions

Pharmacology

Pharmacodynamics

5-MeO-PiPT acts as a serotonin 5-HT1A and 5-HT2A receptor agonist, [1] with an EC50 Tooltip half-maximal effective concentration of 13.8 nM and an efficacy of 89%. [2]

Chemistry

Analogues

Analogues of 5-MeO-PiPT include propylisopropyltryptamine (PiPT), 4-HO-PiPT, 5-MeO-DMT, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-MiPT, 5-MeO-EiPT, and 5-MeO-iPALT (ASR-3001), among others.

See also

References

  1. 1 2 Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, Duggan P, Zilberg G, Capper MJ, Havel V, Russo SJ, Sames D, Wacker D (June 2024). "Structural pharmacology and therapeutic potential of 5-methoxytryptamines". Nature. 630 (8015): 237–246. Bibcode:2024Natur.630..237W. doi:10.1038/s41586-024-07403-2. PMC   11152992 . PMID   38720072.
  2. 1 2 Patentscope. Banister S, Jorgensen W, Jinlong T. Compounds. Patent WO 2023/115167. Retrieved 2025-05-12
  3. ↑ Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia's Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).
  4. ↑ Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN   0-9630096-9-9. OCLC   38503252.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.